Arcutis Biotherapeutics, Inc. (ARQT) stock
ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30368% above fair value
$28.26+0.73 (+2.65%)
Close on Nov 13, 2026Market cap $3.55BP/E 128.5Yield –
Arcutis Biotherapeutics cash
Cash and short-term investments held at the end of each period.
Arcutis Biotherapeutics's cash was $259.46M at Sep 30, 2026. For fiscal 2025 it was $220.98M, down 3.3% from the year before. The highest annual figure on record is $410.82M in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $220.98M | -3.3% |
| FY2024 | Dec 31, 2024 | $228.57M | -16.2% |
| FY2023 | Dec 31, 2023 | $272.79M | -33.6% |
| FY2022 | Dec 31, 2022 | $410.82M | +5.7% |
| FY2021 | Dec 31, 2021 | $388.60M | +35.9% |
| FY2020 | Dec 31, 2020 | $285.98M | +182.3% |
| FY2019 | Dec 31, 2019 | $101.30M | +157.1% |
| FY2018 | Dec 31, 2018 | $39.39M | +1052.5% |
| FY2017 | Dec 31, 2017 | $3.42M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $259.46M | +35.6% |
| Q2 FY2026 | Jun 30, 2026 | $238.55M | +24.8% |
| Q1 FY2026 | Mar 31, 2026 | $224.00M | +12.7% |
| Q4 FY2025 | Dec 31, 2025 | $220.98M | -3.3% |
| Q3 FY2025 | Sep 30, 2025 | $191.38M | -42.2% |
| Q2 FY2025 | Jun 30, 2025 | $191.13M | -47.4% |
| Q1 FY2025 | Mar 31, 2025 | $198.71M | -50.9% |
| Q4 FY2024 | Dec 31, 2024 | $228.57M | -16.2% |
| Q3 FY2024 | Sep 30, 2024 | $331.18M | +45.2% |
| Q2 FY2024 | Jun 30, 2024 | $363.05M | +34.7% |
| Q1 FY2024 | Mar 31, 2024 | $404.48M | +21.3% |
| Q4 FY2023 | Dec 31, 2023 | $272.79M | -33.6% |
| Q3 FY2023 | Sep 30, 2023 | $228.04M | -52.3% |
| Q2 FY2023 | Jun 30, 2023 | $269.60M | -4.9% |
| Q1 FY2023 | Mar 31, 2023 | $333.33M | -3.3% |
| Q4 FY2022 | Dec 31, 2022 | $410.82M | +5.7% |
| Q3 FY2022 | Sep 30, 2022 | $478.20M | +29.7% |
| Q2 FY2022 | Jun 30, 2022 | $283.40M | -31.0% |
| Q1 FY2022 | Mar 31, 2022 | $344.84M | -22.8% |
| Q4 FY2021 | Dec 31, 2021 | $388.60M | +35.9% |
| Q3 FY2021 | Sep 30, 2021 | $368.81M | +94.4% |
| Q2 FY2021 | Jun 30, 2021 | $410.91M | +83.4% |
| Q1 FY2021 | Mar 31, 2021 | $446.47M | +79.1% |
| Q4 FY2020 | Dec 31, 2020 | $285.98M | +182.3% |
| Q3 FY2020 | Sep 30, 2020 | $189.70M | +718.5% |
| Q2 FY2020 | Jun 30, 2020 | $224.00M | +1646.9% |
| Q1 FY2020 | Mar 31, 2020 | $249.30M | +981.6% |
| Q4 FY2019 | Dec 31, 2019 | $101.30M | +157.1% |
| Q3 FY2019 | Sep 30, 2019 | $23.18M | +578.1% |
| Q2 FY2019 | Jun 30, 2019 | $12.82M | – |
| Q1 FY2019 | Mar 31, 2019 | $23.05M | – |
| Q4 FY2018 | Dec 31, 2018 | $39.39M | – |
| Q4 FY2017 | Dec 31, 2017 | $3.42M | – |
See a number that looks wrong?